Articles tagged with: BI-505
FDA Approves Generic Doxil – The FDA recently approved a generic version of Doxil (doxorubicin liposomal), a drug used to treat several different cancers, including multiple myeloma. Doxil was in limited supply from August 2011 to October 2012 due to manufacturing problems. However, the generic version will be readily available in 20 mg or 50 mg vials. Doxil kills cancers cells by damaging their DNA. When used as a treatment for multiple myeloma, the drug is typically combined with Velcade (bortezomib). For more information, please see the related FDA press release
Researchers Develop New Technique To Identify Kyprolis-Resistant Myeloma Cells – Researchers from George Washington University have developed a new technique that can identify multiple myeloma cells resistant to treatment with Kyprolis. The technique involves the use of an imaging dye known as CDy1, which the researchers found effective for identifying myeloma cells with high levels of the gene ABCB1. The cells with high levels of ABCB1 were found, in turn, to be resistant to treatment with Kyprolis (carfilzomib). Based on their findings, the researchers conclude that their new technique may help determine whether levels of the ABCB1 gene can predict how well a multiple myeloma patient will respond to treatment with Kyprolis. For more information, please refer to the study in the American Journal of Hematology (abstract) and the related press release from George Washington University.
MGUS Patients May Have Increased Risk Of Developing MDS – Results of a recent study indicate that, compared to the general population, patients with monoclonal gammopathy of undetermined significance (MGUS) have a 2.4 times higher risk of developing the blood disorder myelodysplastic syndromes (MDS). However, the study also found that MGUS patients do not have a significantly increased risk of developing acute myeloid leukemia or acute lymphoblastic leukemia. For more information, please see the study in the journal Leukemia (abstract).
BI-505 Shows Limited Activity In Multiple Myeloma – Preliminary results from a Phase 1 clinical trial indicate that investigational drug BI-505 shows limited activity in multiple myeloma. However, the study investigators note that the drug had a favorable safety profile. Data from the trial are available for 29 myeloma patients, all of whom had at least two previous treatment regimens before entering the trial. Increasing doses of BI-505 were tested during the study, but the best response seen was stable disease for at least two months, which was observed in 24 percent of the patients. None of the trial participants achieved a partial response or better. BI-505, which is being developed by the Swedish pharmaceutical company BioInvent, is an antibody that binds selectively to myeloma cells, triggering their death. BioInvent has described the trial results as "encouraging," and plans to test the 10 mg/kg dose of BI-505 in a future Phase 2 trial. For more information, please see the BioInvent press release.
Earlier this year, an international group of myeloma experts published a review of ongoing research into new myeloma treatments. This review not only described a wide range of potential new myeloma treatments, but also included the experts' thoughts on where research into new treatments should go in the future.
Given the recent new drug application for carfilzomib and the upcoming annual meeting of the American Society of Hematology -- which undoubtedly will host discussions of many potential new myeloma treatments -- it seems an appropriate time to go back to the …
|FDA Clinical Phase:||1|
BI-505 is a fully human antibody that causes cell death. It binds to the protein ICAM-1 (CD54), which is more common in tumors than in normal tissue. BI-505 may therefore be used to kill cancerous cells that have ICAM-1, including multiple …
Facet Biotech Enrolls First Patient In Elotuzumab Phase 2 Myeloma Study – Facet Biotech announced the first patient’s enrollment in a Phase 2 study of elotuzumab, which is currently being investigated for the treatment of relapsed multiple myeloma. Up to 60 patients will be recruited to receive either 10 mg/kg or 20 mg/kg of elotuzumab in combination with Revlimid (lenalidomide) and low-dose dexamethasone (Decadron). In the Phase 1 trial, 92 percent of patients who completed at least two treatment cycles achieved at least partial response (see related Beacon news). For more information, please see the Facet Biotech press release and the clinical trial description.
Phase 1 Study Of BioInvent’s Drug Candidate BI-505 Treats First Myeloma Patient – BioInvent announced treatment of the first patient with BI-505 in a Phase 1 study evaluating the drug for the treatment of advanced multiple myeloma. The study is recruiting 30 to 40 patients to receive BI-505 intravenously every second week for four weeks or longer. Researchers will evaluate the drug’s safety, activity, and dosage limits. For more information, please see the BioInvent press release and the clinical trial description.
LLS Seminar: Understanding Lab & Radiology Tests – On January 25, the Leukemia & Lymphoma Society (LLS) is holding an informational seminar on how to read and understand medical results, including CT scans, PETs, MRIs, and blood tests. The event will take place at the Katz Cancer Resource Center in Santa Cruz, CA from 11:30 a.m. to 12:30 p.m. For more information or to register, please visit the LLS Web site.
LLS Event: Living With Myeloma – On January 25, the Leukemia & Lymphoma Society (LLS) will host a free program on multiple myeloma from 5 p.m. to 6:30 p.m. at the Moffit Cancer Center in Tampa, FL. Dr. Melissa Alsina will give an overview of myeloma and cover the following topics: the latest in drug therapies, disease and treatment side effects, emotional repercussions and support resources, and clinical trial options. A question and answer session and complimentary dinner will be included. Pre-registration is required. For more information or to register, please visit the LLS Web site.
For a more detailed listing of myeloma related events, please check the Myeloma Beacon Events Calendar.